Technologies

Pharmaceuticals & Vitamin D

Most Recent Inventions

New Hormone Analogs for Treating Hypoparathyroidism

UW–Madison researchers have developed backbone-modified analogs of PTH(1-34). The analogs exhibit advantageous properties; they are biased toward Gs activation/cAMP production relative to β arrestin recruitment.

The analogs were generated via an unconventional strategy in which the backbone of a natural PTHR-1 agonist was altered, rather than the side-chain complement. More specifically, selected α-amino acid residues were systemically replaced with either β-amino acid residues or with unnatural D-stereoisomer α-amino acid residues.

The researchers have shown that backbone-modification can rapidly identify potent agonists with divergent receptor-state selectivity patterns relative to a prototype peptide.
P180053US02

Nylon-3 Polymers to Treat Fungal Infections

UW–Madison researchers have found that nylon-3 polymers developed in their lab display potent antifungal activity against a broad spectrum of common fungal pathogens, with minimal toxicity towards mammalian cells. The polymers have some activity alone, and when used in combination with existing drugs provide synergistic effects against Candida albicans, Cryptococcus neoformans and Aspergillus fumigatus strains, including some resistant strains.

Synergistic combination offers efficacy with significantly reduced amounts of drug and corresponding toxicity, which could potentially expand the relevant patient population.

The polymers were designed to resemble host-defense peptides (HDPs), which are natural molecules that exhibit antimicrobial activities.
P170021US02

Analogs of Diptoindonesin G for Breast Cancer Drug Development

UW–Madison researchers have synthesized analogs of Dip G that have shown a greater ability than the parent molecule to decrease ERα expression and stabilize ERβ in cultured breast cancer cells. The compounds are active for ameliorating, attenuating and halting the growth/metastasis of breast cancers.
P170010US02

Use of Salate Derivatives to Treat Multiple Sclerosis

UW–Madison researchers led by Prof. Hector DeLuca have discovered that two specific salate esters commonly found in sunscreen almost completely prevented experimental autoimmune encephalomyelitis (EAE) development in mice without affecting body weight. Salicylates are well-known nonsteroidal anti-inflammatory drugs (NSAIDs); the complete suppression of EAE by topical administration of homosalate and octyl salicylate is a novel finding.
P160384US02

Efficient In Vitro Assay for Antigen-Specific Tolerance

Building on their work, UW–Madison researchers have now developed a T cell-bound cytokine (T-CBC) assay for detecting and quantifying regulatory T cells specific to self-antigens or donor alloantigens. The new method comprises (a) culturing the subject’s T cells for 24 hours in the presence of one or more target antigens and (b) analyzing the cultured T cells for expression of a marker (EBi3; TGFβ/LAP) indicative of antigen-specific immune suppression.
P160186US02

Most Recent Patents

Engineered Probiotics as Systemic Therapeutic Delivery Platform

UW–Madison researchers have developed bacteria engineered to systemically deliver a therapeutic polypeptide into a subject without the bacteria being substantially introduced into the bloodstream. This platform could be used to non-invasively increase systemic levels of hormones, peptides and potentially single-chain antibodies.

Using this new approach, the researchers engineered a lactic acid bacteria, Lactobacillus reuteri, to systemically deliver interleukin-22 (IL-22) in mice. The method is not limited to IL-22; other potential polypeptides include IL-35, insulin, leptin, a peptide inhibitor of PCSK9 and endolysin.
P160109US02

Inhibiting Metadherin/SND1 Interaction to Treat Cancer

UW–Madison researchers and collaborators have developed a method to fight tumor growth and metastasis using novel peptides that inhibit interaction between MTDH and a protein called SND1.

The researchers found that MTDH-SND1 protein interaction is important for the expansion and function of prostate tumors as well as luminal and basal breast tumor initiating cells. Their work provides novel peptides that target this protein complex to help control tumor initiation, recurrence and metastasis by combating tumor initiating cells, with minimal impact on normal tissues.
P140424US02

Compound Combination Targets Bacterial Virulence

The researchers have discovered that two lead compounds (E22/M64) can be combined to target multiple QS pathways at the same time (Rhl/Pqs), resulting in enhanced activity against P. aeruginosa and potentially other pathogens. This new cocktail approach is superior because it attenuates virulence factor production across a range of relevant environments where single compounds fail.
P160176US02